4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evolus, Inc. (EOLS) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Newport Beach, United States with about 350 employees. Its market capitalization is roughly $450 million. In the fiscal year ended 2025-12-31, EOLS reported $297M in revenue and ($52M) in net income.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
Interactive charts & full statements → Open the EOLS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $297M | $266M | $202M | $149M | — |
| Gross Profit | $197M | $182M | $138M | $90M | — |
| Operating Income (EBIT) | ($38M) | ($27M) | ($45M) | ($60M) | — |
| Net Income | ($52M) | ($50M) | ($62M) | ($74M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $73M | $90M | $69M | $69M | $68M |
| Gross Profit | $49M | $59M | $46M | $45M | $47M |
| Operating Income (EBIT) | ($7M) | ($0M) | ($10M) | ($14M) | ($13M) |
| Net Income | ($11M) | $0M | ($16M) | ($17M) | ($19M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $226M | $233M | $189M | $178M | — |
| Total Liabilities | $249M | $227M | $210M | $160M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EOLS viewer.
About TickerBase · Data methodology & sources